Weekly injection for diabetes and weight loss: what you actually need to know

The misconception that one jab covers everything the same way

A common assumption runs something like this: if a weekly injection treats both diabetes and weight, it must work identically for both, and anyone with either condition can get the same medicine the same way. That is not quite right, and the distinction matters practically.

Tirzepatide (Mounjaro) activates two gut-hormone receptors (GIP and GLP-1) making it the only dual-agonist medicine of its kind licensed in the UK. Semaglutide (Wegovy) targets GLP-1 only. Both slow gastric emptying, reduce appetite and improve blood-sugar control, but their UK licences are separate and specific. Mounjaro is licensed for weight management and type 2 diabetes. Wegovy is licensed for weight management. The semaglutide product licensed for type 2 diabetes is Ozempic, which carries a different dose schedule and is a different product entirely, the relationship between weight-loss injections and diabetes medicines is one of the most misunderstood areas we see. Both Mounjaro and Wegovy carry a Black Triangle (▼) designation from the MHRA, meaning additional monitoring is in place while longer-term real-world data accumulates.

So if you have type 2 diabetes and are seeking weight-management treatment, the choice of medicine, the starting dose, and how it interacts with existing diabetes drugs are all clinician decisions, not ones you can resolve by comparing product pages. The NHS tirzepatide medicines page sets out the licensed indications clearly for both conditions.

What happens to your diabetes drugs when you start a weekly injection for weight

This is where the situation gets genuinely important, and it is the part that catches people out. Both tirzepatide and semaglutide lower blood glucose. If you are already taking a sulfonylurea (such as gliclazide) or insulin, adding one of these medicines without adjusting your existing regimen raises the risk of hypoglycaemia, blood sugar going too low.

NHS England's guidance on weight-management injections is explicit on this point: your full medication list must be reviewed by a clinician before treatment starts, and your GP should be informed. At nume, every consultation is read in full by a GPhC-registered Independent Prescriber (a real clinician, not software) who considers your diabetes history, current prescriptions and any relevant test results before a decision is made. If a GP letter or medication evidence is needed, the prescriber will ask for it.

The flip side is also worth knowing: for some people with type 2 diabetes, effective weight loss on these medicines leads to meaningful improvements in blood-sugar control, and over time some find they need less diabetes medication. That is a good outcome, but it still needs medical oversight, not self-management. Your GP is the right person to review and adjust your diabetes drugs as your weight changes. More background on the newer injections licensed across both conditions is available if you want to read further before consulting.

Who is suited to these medicines, and who needs to be careful

The private licensed eligibility threshold is a BMI of 30 or above, or 27 or above if you have at least one weight-related condition, type 2 diabetes, prediabetes, hypertension, high cholesterol or obstructive sleep apnoea all count. For some ethnic backgrounds, UK clinical guidance applies thresholds that are 2.5 kg/m² lower. But the number on the scale is only the starting point; the prescriber weighs the whole picture.

Certain situations call for particular care. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules these medicines out. Severe or unexplained pancreatitis in your history is a flag the prescriber will take seriously; the MHRA issued a Drug Safety Update in January 2026 specifically noting that severe, persistent abdominal pain radiating to the back is a reason to seek urgent help. Anyone due surgery should tell the anaesthetist they are taking a GLP-1 or dual-agonist medicine beforehand.

Pregnancy, breastfeeding and actively trying to conceive are all situations where these medicines are not recommended. Women taking oral contraceptive pills starting tirzepatide should add a non-oral method (condoms, for example) for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced during that period. There is no equivalent evidence of this interaction for semaglutide, but contraception should still be used throughout. If any of this applies to you, the right conversation is with your GP or prescriber before treatment begins, not after.

If you are not sure where you stand, there is specific guidance on these medicines for people with prediabetes that covers the eligibility picture in more detail.

Getting access: NHS routes versus a regulated private service

NHS access to these medicines is phased and carries strict criteria. As of June 2025, tirzepatide on the NHS requires a BMI of 40 or above plus four or more qualifying conditions; from around June 2026 that broadened to include a BMI of 35 to 39.9 with four or more conditions. Wegovy on the NHS is routed through specialist weight management services, where waiting lists can stretch considerably. GP practices can now prescribe tirzepatide under the 2026/27 GP contract, but participation varies by practice and area.

For people who meet the private eligibility criteria but do not meet the NHS thresholds, or who simply cannot wait, a regulated online pharmacy is the legal private route. At nume, there is no subscription and no auto-renewal; every repeat order is reviewed by a prescriber before it goes anywhere. If you are weighing up your options, it is worth reading about how a weekly weight loss injection works in practice so you know what to expect before you commit. Orders placed before 12pm Monday to Friday are dispatched the same day once approved, arriving by tracked DPD the next working day, worth bearing in mind if you are planning around a bank holiday or a Monday order after a busy weekend. Plain, unbranded packaging; no fuss.

Pricing varies by dose and provider. The cost context for weight-loss injections is worth reading before you compare headline figures, because what those prices include (or exclude) differs considerably. If keeping costs manageable is a priority, there is a dedicated page covering the best value weight loss injections currently available that sets out where your money goes at each price point. For a detailed look at all the treatment options available through nume, the weight-loss treatment overview covers the full range.